With the selected dose-adjusted mode, some HIF-PHIs appeared to be a potential treatment for DD-CKD patients when compared with rhEPO, due to its effectiveness in decreasing the risk of RBC transfusion rate or regulating iron or lipid metabolism while achieving target Hb levels (Table 2). The gene discussed is GSTM1; the disease is chronic kidney disease.